Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Lyell Immunopharma acquires ImmPACT Bio to boost CAR T-cell therapy | 1 | Investing.com | ||
Do | Lyell Immunopharma übernimmt ImmPACT Bio zur Stärkung der CAR-T-Zelltherapie | 2 | Investing.com Deutsch | ||
Do | Lyell Immunopharma, Inc: Lyell Immunopharma Completes Acquisition of ImmPACT Bio | 1 | GlobeNewswire (Europe) | Acquisition strengthens Lyell's clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to initiate pivotal development in 2025 in patients... ► Artikel lesen | |
Mi | Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy | 1 | Benzinga.com | ||
28.10. | Lyell Immunopharma behält neutrales Rating nach Übernahme | 1 | Investing.com Deutsch | ||
28.10. | Lyell Immunopharma shares maintain neutral rating on acquisition | 1 | Investing.com | ||
25.10. | Lyell Immunopharma-Aktie erreicht 52-Wochen-Tief bei 1,05 US-Dollar | 1 | Investing.com Deutsch | ||
25.10. | Lyell Immunopharma stock hits 52-week low at $1.05 | 2 | Investing.com | ||
24.10. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
09.10. | Lyell Immunopharma stock hits 52-week low at $1.09 | 1 | Investing.com | ||
04.10. | Lyell Immunopharma, Inc: Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting | 1 | GlobeNewswire (USA) | ||
24.09. | Lyell Immunopharma, Inc: Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day | 4 | GlobeNewswire (USA) | ||
09.09. | Lyell Immunopharma stock hits 52-week low at $1.14 | 1 | Investing.com | ||
28.08. | Lyell Immunopharma, Inc: Lyell Immunopharma Announces Participation in September Investor Conferences | 2 | GlobeNewswire (USA) | ||
08.08. | Lyell Immunopharma reports Q2 results | 1 | Seeking Alpha | ||
07.08. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
07.08. | Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 | 70 | GlobeNewswire (Europe) | Reported dose-dependent antitumor clinical activity in patients with relapsed/refractory triple-negative breast cancer from the Phase 1 trial of LYL797, a ROR1-targeted Chimeric Antigen Receptor (CAR)... ► Artikel lesen | |
26.06. | Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial | 1 | Benzinga.com | ||
26.06. | Lyell Immunopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
26.06. | Lyell Immunopharma, Inc: Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology | 147 | GlobeNewswire (Europe) | Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MEDIGENE | 1,600 | -1,53 % | PTA-News: Medigene AG: Medigene präsentiert auf folgenden Investorenkonferenzen | DJ PTA-News: Medigene AG: Medigene präsentiert auf folgenden Investorenkonferenzen
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (pta/29.10.2024/11:30) - Die Medigene AG (... ► Artikel lesen | |
MODERNA | 49,300 | +0,12 % | Moderna, Inc.: Moderna to Present at Upcoming Conferences in November 2024 | CAMBRIDGE, MA / ACCESSWIRE / October 31, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:Guggenheim's Inaugural Healthcare Innovation... ► Artikel lesen | |
VALNEVA | 2,642 | -0,15 % | Valneva Aktie: Trendwendechance zum Greifen nah | Spannende Situation bei der Valneva Aktie: Der Aktienkurs des französisch-österreichischen Biotech-Unternehmens stand lange unter Druck, hat in den letzten rund fünf Wochen allerdings im Bereich 2,46/2... ► Artikel lesen | |
NOVAVAX | 8,280 | -1,21 % | Novavax, Inc.: Åsa Manelius Named Managing Director of Novavax AB Site | GAITHERSBURG, Md., Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today announced that Åsa Manelius... ► Artikel lesen | |
EPIGENOMICS | 1,000 | +11,11 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
CRISPR THERAPEUTICS | 46,500 | -0,43 % | Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers | ||
INOVIO PHARMACEUTICALS | 5,090 | +0,20 % | Inovio Pharmaceuticals Inc. Q2 Loss Decreases | WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals Inc. (INO) revealed Loss for second quarter that decreased from the same period last yearThe company's bottom line totaled -$32.24 million, or -$1.19... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 1,600 | -0,27 % | Sangamo BioSciences-Aktie erreicht 52-Wochen-Hoch von 2,09 US-Dollar | ||
INFLARX | 1,434 | -0,14 % | InflaRx Aktie: Starkes Vertrauen am Markt! | ||
INTELLIA THERAPEUTICS | 14,060 | +0,90 % | Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Capital Advisors Inc. OK | ||
VIKING THERAPEUTICS | 57,96 | -0,17 % | Nach Kursvervierfachung: Viking Therapeutics: "Großartiger" Test bei Adipositas-Pille - Aktie explodiert! | Die Aktie von Viking Therapeutics haussiert am Montag um 26 Prozent, nachdem eine klinische Studie mit seiner experimentellen oralen Gewichtsabnahmepille vielversprechende Ergebnisse gezeigt hat.Eine... ► Artikel lesen | |
SCORPIUS | 0,740 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually | DURHAM, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or the "Company"), an integrated biomanufacturing company, today announced the implementation... ► Artikel lesen | |
VIVORYON THERAPEUTICS | 2,240 | -0,88 % | Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 | Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024
Selected for late-breaking oral presentation at ASN kidney week, the... ► Artikel lesen | |
EDITAS MEDICINE | 2,655 | +0,42 % | Editas Medicine, Inc.: Editas Medicine Announces Third Quarter 2024 Results and Business Updates | Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,424 | +2,91 % | Defence Therapeutics Inc.: Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs | Vancouver, British Columbia--(Newsfile Corp. - November 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen |